Dermata Therapeutics, INC Schedule 13D activist filings

Dermata Therapeutics CFO Kyri K. Van Hoose reports beneficial ownership of 9.0% of the company's common stock following a private placement and warrant amendments.

Gerald T. Proehl, President and CEO of Dermata Therapeutics, Inc., updated his beneficial ownership to 17.3% of the company's common stock.

Dermata Therapeutics CEO Gerald T. Proehl filed an amendment to his Schedule 13D, confirming beneficial ownership of 19.6% of the company's common stock.

Dermata Therapeutics' CEO Gerald T. Proehl increased his beneficial ownership to 24.7% following participation in a private placement, while Proehl Investment Ventures LLC's stake fell below 5%.

Gerald T. Proehl and Proehl Investment Ventures LLC filed an amended Schedule 13D to correct their reported beneficial ownership percentage in Dermata Therapeutics, Inc. to 13.3% based on an updated outstanding share count.

Gerald T. Proehl and Proehl Investment Ventures LLC have filed Amendment No. 6 to their Schedule 13D, reaffirming their beneficial ownership of 7.8% of Dermata Therapeutics, Inc.'s common stock as of March 27, 2025.

Dermata Therapeutics, Inc.'s CEO, Gerald T. Proehl, and his investment entity, Proehl Investment Ventures LLC, have significantly increased their beneficial ownership in the company to 15.0% and 14.9% respectively, primarily through participation in a recent private placement.

Gerald T. Proehl and Proehl Investment Ventures LLC report increased beneficial ownership in Dermata Therapeutics following a recent private placement.